Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. (3rd July 2018)

• Record Type: Journal Article
• Authors: Strawn, Jeffrey R.; Geracioti, Laura; Rajdev, Neil; Clemenza, Kelly; Levine, Amir
• Is Part Of: Expert opinion on pharmacotherapy. Volume 19:Number 10(2018)
• Page Start: 1057
• Page End: 1070
• Publication Date: 2018-07-03
• Subjects: Selective Serotonin Reuptake Inhibitor (SSRI) -- Selective Serotonin Norepinephrine Reuptake Inhibitor (SNRI) -- antidepressants -- pediatric -- adult -- benzodiazepine -- buspirone; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2018.1491966
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Generalized anxiety disorder (GAD) often begins during adolescence or early adulthood and persists throughout the lifespan. Randomized controlled trials support the efficacy of selective serotonin and selective serotonin norepinephrine reuptake inhibitors (SSRIs and SNRIs, respectively), as well as benzodiazepines, azapirones, anti-adrenergic medications, melatonin analogs, second-generation antipsychotics, kava, and lavender oil in GAD. However, psychopharmacologic treatment selection requires clinicians to consider multiple factors, including age, co-morbidity, and prior treatment. Areas covered : The authors review the literature concerning pharmacotherapy for pediatric and adult patients with GAD with specific commentary on the efficacy and tolerability of selected agents in these age groups. The authors describe an algorithmic approach to the pediatric and adult patient with GAD and highlight considerations for the use of selected medications in these patients. Expert opinion : In adults with GAD, SSRIs and SNRIs represent the first-line psychopharmacologic treatment while second-line pharmacotherapies include buspirone, benzodiazepines, SGAs, and pregabalin. In pediatric patients with GAD, SSRIs should be considered the first line pharmacotherapy and psychotherapy enhances antidepressant response.